ArticleBMJ open respiratory research2026
Chronic obstructive pulmonary disease as a systemic risk factor for cancer: a nationwide cohort study in Korea.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is increasingly recognised as a systemic condition with extrapulmonary comorbidities including malignancy. While the association between COPD and lung cancer is well established, evidence for extrapulmonary cancers, particularly after accounting for lifestyle, demographic and socioeconomic factors, remains limited.
methodsWe conducted a nationwide population-based cohort study using the Korean National Health Insurance Service-Health Screening Cohort (2002-2019). After exclusions and propensity score overlap weighting, 532 174 patients with COPD and 1 891 601 matched controls were included. COPD and exacerbations were defined using International Classification of Diseases, 10th Revision codes and treatment records. Cox proportional hazards models and E-value analyses were used to estimate associations and assess the potential impact of unmeasured confounding.
resultsDuring up to 16 years of follow-up, COPD was associated with a 52% higher overall cancer risk (HR 1.52, 95% CI 1.50 to 1.53), independent of demographic, lifestyle and clinical factors. Increased risks were observed for 11 of 14 site-specific cancers, with the strongest associations for lung (HR 3.68), bladder (HR 1.58), haematological (HR 1.45) and kidney cancers (HR 1.43). COPD exacerbations were also associated with increased overall cancer risk (HR 1.48, 95% CI 1.46 to 1.50), with broadly similar patterns across site-specific cancers. Associations were consistent across sex, age and smoking strata and were unlikely to be explained by unmeasured confounding based on E-value analyses.
conclusionsCOPD and exacerbations were associated with increased risks of overall and multiple site-specific cancers beyond the lungs. These findings support the systemic nature of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.